Closed April 2009
Stiefel Laboratories Inc. was an American-based private company with a 160-year heritage in dermatology products, an expansive R&D pipeline, and more than 275 brands sold in nearly 100 countries.
Advised Stiefel on the sale of the company to GlaxoSmithKline plc (GSK) after conducting a highly competitive auction. Total transaction value was $3.6 billion.
Stiefel’s objective was to be maximize value for its shareholders. Stiefel and Blackstone determined that a sale process may be able to create superior shareholder value and pursued a targeted auction including the most viable strategic parties. GSK’s acquisition of Stiefel creates a world-leading specialist dermatology business under the leadership of key Stiefel senior management.